TP53 and cancer: Longitudinal sample collection from the 224 participants with LFS enrol into the MILI study will enable us to track changes in circulating biomarkers, such as anti-p53 antibodies, cell-free DNA and methylation profiling, comparing expression of these markers in those diagnosed with cancer versus those who remain cancer-free during the 5-year study.